Physician profile
Constance Bradley
NPI 1528546363
$6,653.08
in general payments reported to CMS, 2019-2025
16 companies · $876 in 2025
The $876 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873 · 2022: $1,298 · 2023: $1,670 · 2024: $1,936 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,246 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,246.21 |
| Education | $235.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,771.70 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,395.90 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $877.32 | 2021-2024 | Caplyta |
| Abbvie INC. | $739.36 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $632.08 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $475.43 | 2021-2024 | Lybalvi |
| Lundbeck LLC | $214.57 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.68 | 2025 | Relistor, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $96.48 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $60.39 | 2024 | Auvelity |
| Novo Nordisk INC | $57.15 | 2023 | Wegovy |
| Vanda Pharmaceuticals INC. | $56.29 | 2024-2025 | Fanapt |
| Averitas Pharma INC. | $56.25 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $31.79 | 2022 | |
| Indivior INC. | $23.80 | 2023 | Perseris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $17.89 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.